

PRODUCT LICENSE APPLICATION

PLA-0002-XXX-CY04 *Val Q*

MERCK & CO., INC.

Measles, Mumps and Rubella Virus Vaccine Live



DCC Volume Sequence No. 157802

Table 4: Clinical Complaints for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 310 at Lankenau Hospital Outpatient Clinic from 9/26/68 to 10/10/68 (Study #212)

| Clinical Complaint | Total Vaccinees | | | | Children Initially Seronegative to Measles, Mumps and Rubella | | | |
|---------------------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 10 (25.6%) | 9 (23.1%) | 5 (12.8%) | 5 (12.8%) | 8 (26.7%) | 9 (30.0%) | 5 (16.7%) | 3 (10.0%) |
| Otitis | | | | 1 (2.6%) | | | | 1 (3.3%) |
| Lymphadenopathy | | 1 (2.6%) | | | | | | |
| Gastrointestinal | 1 (2.6%) | 3 (7.7%) | | | 1 (3.3%) | 2 (6.7%) | | |
| Rash (not measles) | 1 (2.6%) | 3 (7.7%) | 2 (5.1%) | 1 (2.6%) | 1 (3.3%) | 2 (6.7%) | 2 (6.7%) | 1 (3.3%) |
| Irritability | 2 (5.1%) | 5 (12.8%) | 2 (5.1%) | | 2 (6.7%) | 3 (10.0%) | 2 (6.7%) | |
| Malaise | 1 (2.6%) | | | | | | | |
| Irrelevant | | 2 (5.1%) | 1 (2.6%) | 1 (2.6%) | | 2 (6.7%) | 1 (3.3%) | |
| No Complaint | 25 (64.1%) | 21 (53.8%) | 30 (76.9%) | 32 (82.0%) | 19 (63.3%) | 15 (50.0%) | 21 (70.0%) | 25 (83.3%) |
| Total Subjects | 39 | 39 | 39 | 39 | 30 | 30 | 30 | 30 |

Table 5: Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 92126 and for Their Unvaccinated Contact Controls (Study 232)

| Clinical Complaints | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|-----------------------------------|--------------------------|---------------|---------------|---------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | | 2 (6.4%) | 3 (9.7%) | 2 (6.4%) | 15 (15.0%) | 20 (20.0%) | 12 (12.0%) | 14 (14.0%) | 13 (15.8%) | 16 (19.5%) | 10 (12.2%) | 9 (11.0%) |
| Otitis | | | | | 1 (1.0%) | 1 (1.0%) | | 2 (2.0%) | 1 (1.2%) | 1 (1.2%) | | 1 (1.2%) |
| Swollen Glands | | | | | | 1 (1.0%) | | | | 1 (1.2%) | | |
| Conjunctivitis | | | | | | 1 (1.0%) | | | | 1 (1.2%) | | |
| Gastrointestinal | | | | | 11 (11.0%) | 11 (11.0%) | 6 (6.0%) | 6 (6.0%) | 9 (11.0%) | 10 (12.2%) | 6 (7.3%) | 5 (6.1%) |
| Rash | 1 (3.2%) | 1 (3.2%) | | | 3 (3.0%) | 3 (3.0%) | 2 (2.0%) | 3 (3.0%) | 3 (3.6%) | 3 (3.6%) | 2 (2.4%) | 3 (3.6%) |
| Irritability | | | | | 4 (4.0%) | 6 (6.0%) | 4 (4.0%) | 4 (4.0%) | 4 (4.9%) | 5 (6.1%) | 4 (4.9%) | 4 (4.9%) |
| Malaise | | | | | 1 (1.0%) | | | | 1 (1.2%) | | | |
| Irrelevant | | | | | | | | 1 (1.0%) | | | | 1 (1.2%) |
| Anorexia | | | | | 2 (2.0%) | 2 (2.0%) | 1 (1.0%) | 1 (1.0%) | 2 (2.4%) | 2 (2.4%) | 1 (1.2%) | 1 (1.2%) |
| Swelling of Face | | | | | | 1 (1.0%) | 1 (1.0%) | | | 1 (1.2%) | 1 (1.2%) | |
| Flush | | | | | | | 1 (1.0%) | | | | 1 (1.2%) | |
| Viral Infection | | | | | | | | 2 (2.0%) | | | | 2 (2.4%) |
| Measles-like Rash | | | | | | 4 (4.0%) | 1 (1.0%) | | | 4 (4.9%) | 1 (1.2%) | |
| Fatigue | | | | | 2 (2.0%) | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | 1 (1.2%) | | | |
| Toothing | | | | | 4 (4.0%) | 2 (2.0%) | 1 (1.0%) | 1 (1.0%) | 3 (3.6%) | 1 (1.2%) | 1 (1.2%) | 1 (1.2%) |
| No Complaints | 30 (96.8%) | 28 (90.3%) | 28 (90.3%) | 29 (93.5%) | 70 (70.0%) | 64 (64.0%) | 76 (76.0%) | 71 (71.0%) | 57 (69.5%) | 52 (63.4%) | 61 (74.4%) | 60 (73.2%) |
| Physician's Surveillance Negative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | | | |
| Total Subjects | 32 | 32 | 32 | 32 | 101 | 101 | 101 | 101 | 82 | 82 | 82 | 82 |

Table 5: Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 92127 and for Their Unvaccinated Contact Controls (Study 232)

| Clinical Complaints | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|-----------------------------------|--------------------------|---------------|---------------|---------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 5 (16.1%) | 8 (25.8%) | 3 (9.7%) | 3 (9.7%) | 20 (20.6%) | 30 (30.9%) | 14 (14.4%) | 16 (16.5%) | 15 (20.0%) | 24 (32.0%) | 10 (13.3%) | 14 (18.7%) |
| Otitis | | | 1 (3.2%) | | 2 (2.1%) | 3 (3.1%) | 1 (1.0%) | 3 (3.1%) | 2 (2.7%) | 3 (4.0%) | 1 (1.3%) | 3 (4.0%) |
| Swollen Glands | | | 1 (3.2%) | | | 1 (1.0%) | | | | | | |
| Gastrointestinal | 1 (3.2%) | 2 (6.4%) | | | 9 (9.3%) | 6 (6.2%) | 3 (3.1%) | 2 (2.1%) | 6 (8.0%) | 4 (5.3%) | 3 (4.0%) | 1 (1.3%) |
| Headache | | | | 1 (3.2%) | | | | | | | | |
| Viral Infection | | | | 1 (3.2%) | | | | 1 (1.0%) | | | | |
| Conjunctivitis | | | | | | | 1 (1.0%) | 1 (1.0%) | | | | |
| Rash | | | | | 5 (5.2%) | 3 (3.1%) | | 1 (1.0%) | 5 (6.7%) | 2 (2.7%) | | 1 (1.3%) |
| Irritability | | | | | 7 (7.2%) | 7 (7.2%) | 3 (3.1%) | 2 (2.1%) | 6 (8.0%) | 5 (6.7%) | 1 (1.3%) | 1 (1.3%) |
| Chicken pox | | | | | | | | 1 (1.0%) | | | | 1 (1.3%) |
| Irrelevant | | | | | | | 1 (1.0%) | 3 (3.1%) | | | | 1 (1.3%) |
| Fever | | | | | | 1 (1.0%) | 1 (1.0%) | | | 1 (1.3%) | 1 (1.3%) | |
| Anorexia | | | | | 1 (1.0%) | 1 (1.0%) | | | 1 (1.3%) | 1 (1.3%) | | |
| Genitourinary Infection | | | | | | | 1 (1.0%) | | | | | |
| Flush | | | | | | 1 (1.0%) | | | | 1 (1.3%) | | |
| Scarlatina | | | | | | | 1 (1.0%) | | | | 1 (1.3%) | |
| Allergy | | | | | | | 1 (1.0%) | | | | 1 (1.3%) | |
| Measles-like Rash | | | | | | 3 (3.1%) | 1 (1.0%) | | | 3 (4.0%) | 1 (1.3) | |
| Teething | | | | | 3 (3.1%) | 3 (3.1%) | 4 (4.1%) | 1 (1.0%) | 3 (4.0%) | 2 (2.7%) | 2 (2.7%) | 1 (1.3%) |
| No Complaints | 25 (80.6%) | 22 (71.0%) | 27 (87.1%) | 27 (87.1%) | 62 (63.9%) | 57 (58.8%) | 72 (74.2%) | 71 (73.2%) | 47 (62.7%) | 43 (57.3%) | 59 (78.7%) | 55 (73.3%) |
| Negative Physician's Surveillance | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 1 | 1 | 1 | 1 |
| Total Subjects | 34 | 34 | 34 | 34 | 101 | 101 | 101 | 101 | 76 | 76 | 76 | 76 |

Table 5: Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 95400 and for Their Unvaccinated Contact Controls (Study 232)

| Clinical Complaints | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|-----------------------------------|--------------------------|---------------|---------------|---------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 4 (10.5%) | 7 (18.4%) | 5 (13.2%) | 6 (15.8%) | 15 (15.2%) | 22 (22.2%) | 10 (10.1%) | 13 (13.1%) | 13 (18.6%) | 16 (22.8%) | 8 (11.4%) | 10 (14.3%) |
| Otitis | | | | 1 (2.6%) | | 2 (2.0%) | 2 (2.0%) | 4 (4.0%) | | 1 (1.4%) | 2 (2.8%) | 3 (4.3%) |
| Gastrointestinal | 2 (5.3%) | | 1 (2.6%) | | 1 (1.0%) | 4 (4.0%) | 3 (3.0%) | 3 (3.0%) | | 4 (5.7%) | 2 (2.8%) | 1 (1.4%) |
| Rash | 1 (2.6%) | 1 (2.6%) | 1 (2.6%) | 1 (2.6%) | 2 (2.0%) | 1 (1.0%) | 3 (3.0%) | 1 (1.0%) | 2 (2.8%) | 1 (1.4%) | 2 (2.8%) | |
| Headache | 1 (2.6%) | | | | | 1 (1.0%) | | 1 (1.0%) | | | | 1 (1.4%) |
| Irritability | 2 (5.3%) | | | | 7 (7.1%) | 8 (8.2%) | 1 (1.0%) | 1 (1.0%) | 5 (7.1%) | 7 (10.0%) | 1 (1.4%) | |
| Anorexia | 1 (2.6%) | | | | 1 (1.0%) | 2 (2.0%) | | 1 (1.0%) | 1 (1.4%) | 2 (2.8%) | | 1 (1.4%) |
| Viral Infection | | | 1 (2.6%) | | | | | 2 (2.0%) | | | | 2 (2.8%) |
| Fatigue | | 1 (2.6%) | | | | | | | | | | |
| Teething | | 1 (2.6%) | | | 1 (1.0%) | 5 (5.0%) | 3 (3.0%) | 5 (5.0%) | 1 (1.4%) | 5 (7.1%) | 2 (2.8%) | 4 (5.7%) |
| Local Reaction - Injection Site | | | | | 2 (2.0%) | | | | 1 (1.4%) | | | |
| Malaise | | | | | | 1 (1.0%) | | | | 1 (1.4%) | | |
| Chicken Pox | | | | | 1 (1.0%) | | | | 1 (1.4%) | | | |
| Irrelevant | | | | | 1 (1.0%) | | | 2 (2.0%) | 1 (1.4%) | | | 2 (2.8%) |
| Flush | | | | | | 1 (1.0%) | | | | 1 (1.4%) | | |
| Pain | | | | | | | 1 (1.0%) | | | | 1 (1.4%) | |
| Measles-like Rash | | | | | | 2 (2.0%) | | | | 2 (2.8%) | | |
| Whooping Cough | | | | | 1 (1.0%) | | | | 1 (1.4%) | | | |
| Swollen Glands | | | | | | 2 (2.0%) | | | | 2 (2.8%) | | |
| No Complaints | 27 (71.0%) | 29 (76.3%) | 30 (78.9%) | 30 (78.9%) | 71 (71.7%) | 62 (62.6%) | 81 (81.8%) | 69 (69.7%) | 47 (67.1%) | 40 (57.1%) | 56 (80.0%) | 48 (68.6%) |
| Physician's Surveillance Negative | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | | | | |
| Total Subjects | 40 | 40 | 40 | 40 | 101 | 101 | 101 | 101 | 70 | 70 | 70 | 70 |

Table 4: Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 92127 and for Their Unvaccinated Contact Controls (Study 220-220B)

| Clinical Complaints | Adult Contact Controls | | | | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles, Mumps, & Rubella | | | |
|---------------------------------------|------------------------|----------------|----------------|----------------|--------------------------|---------------|---------------|---------------|-----------------------|----------------|----------------|----------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 3 (1.8%) | 13 (7.7%) | 5 (3.0%) | 5 (3.0%) | 2 (5.6%) | 9 (25.0%) | 6 (16.7%) | 4 (11.1%) | 52 (14.2%) | 74 (20.3%) | 48 (13.2%) | 34 (9.3%) | 10 (12.2%) | 16 (19.5%) | 9 (11.0%) | 8 (9.8%) |
| Otitis | 1 (0.6%) | 6 (3.6%) | 4 (2.4%) | 1 (0.6%) | | 1 (2.8%) | | | 1 (0.3%) | 6 (1.6%) | | 1 (0.3%) | | 3 (3.7%) | | |
| Swollen Glands | 1 (0.6%) | 4 (2.4%) | 3 (1.8%) | | | 2 (5.6%) | | | | 3 (0.8%) | 2 (0.5%) | | | 1 (1.2%) | | |
| Conjunctivitis | 2 (1.2%) | 2 (1.2%) | | | 1 (2.8%) | 1 (2.8%) | 1 (2.8%) | 1 (2.8%) | 3 (0.8%) | 11 (3.0%) | 4 (1.1%) | 2 (0.5%) | | 1 (1.2%) | 1 (1.2%) | 1 (1.2%) |
| Gastrointestinal | 5 (3.0%) | 13 (7.7%) | 5 (3.0%) | 4 (2.4%) | 2 (5.6%) | 10 (27.8%) | 7 (19.4%) | 5 (13.9%) | 41 (11.2%) | 82 (22.5%) | 34 (9.3%) | 31 (8.5%) | 7 (8.5%) | 22 (26.8%) | 9 (11.0%) | 8 (9.8%) |
| Rash | | | | | | | | | | | 1 (0.3%) | 1 (0.3%) | | | | |
| Headache | 33 (19.6%) | 48 (28.6%) | 16 (9.5%) | 9 (5.4%) | 1 (2.8%) | 2 (5.6%) | | | 12 (3.3%) | 14 (3.8%) | 5 (1.4%) | 2 (0.5%) | 1 (1.2%) | 4 (4.9%) | | 1 (1.2%) |
| Irritability | 5 (3.0%) | 9 (5.4%) | 2 (1.2%) | 1 (0.6%) | 2 (5.6%) | 8 (22.2%) | 5 (13.9%) | 6 (16.7%) | 23 (6.3%) | 81 (22.2%) | 40 (11.0%) | 21 (5.8%) | 8 (9.8%) | 27 (32.9%) | 13 (15.9%) | 8 (9.8%) |
| Malaise | 23 (13.7%) | 34 (20.2%) | 13 (7.7%) | 6 (3.5%) | 3 (8.3%) | 6 (16.7%) | 5 (13.9%) | 4 (11.1%) | 52 (14.2%) | 72 (19.7%) | 33 (9.0%) | 20 (5.5%) | 16 (19.5%) | 20 (24.4%) | 8 (9.8%) | 3 (3.7%) |
| Irrelevant | 1 (0.6%) | | | | | | | | | | | | | | | |
| Fever | 2 (1.2%) | 6 (3.6%) | 1 (0.6%) | 1 (0.6%) | 1 (2.8%) | 5 (13.9%) | 3 (8.3%) | 2 (5.6%) | 18 (4.9%) | 54 (14.8%) | 19 (5.2%) | 4 (1.1%) | 3 (3.7%) | 11 (13.4%) | 5 (6.1%) | |
| Anorexia | 14 (8.3%) | 20 (11.9%) | 8 (4.8%) | 5 (3.0%) | 4 (11.1%) | 9 (25.0%) | 4 (11.1%) | 2 (5.6%) | 33 (9.0%) | 70 (19.2%) | 30 (8.2%) | 19 (5.2%) | 10 (12.2%) | 18 (22.0%) | 9 (11.0%) | 6 (7.3%) |
| Exanthema | | | | | | 1 (2.8%) | 1 (2.8%) | | 1 (0.3%) | 3 (0.8%) | 3 (0.8%) | 4 (1.1%) | | 1 (1.2%) | 1 (1.2%) | 2 (2.4%) |
| Rubella-like Rash | | | | | | | | | | 1 (0.3%) | 1 (0.3%) | | | | | |
| Aggravated Infection - Injection Site | | | | | | | | | | | | 1 (0.3%) | | | | |
| Measles-like Rash | | | | | | | | | | | | 1 (0.3%) | | | | |
| No Complaints | 113 (67.3%) | 103 (61.3%) | 131 (78.0%) | 148 (88.1%) | 27 (75.0%) | 17 (47.2%) | 22 (61.1%) | 25 (69.4%) | 231 (62.9%) | 165 (45.2%) | 251 (68.8%) | 282 (77.3%) | 52 (63.4%) | 37 (45.1%) | 55 (67.1%) | 62 (75.6%) |
| Physician's Surveillance Negative | 15 | 15 | 15 | 15 | | | | | | 2 | 2 | 2 | | | | |
| Total Subjects | 183 | 183 | 183 | 183 | 36 | 36 | 36 | 36 | 367 | 367 | 367 | 367 | 82 | 82 | 82 | 82 |

Table 4: Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 92126 and for their Unvaccinated Contact Controls (Study 220 and 220B)

| Clinical Complaint | Adult Contact Controls | | | | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|-----------------------------------|------------------------|----------------|----------------|----------------|--------------------------|---------------|---------------|---------------|-----------------------|----------------|----------------|----------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 6 (3.8%) | 9 (5.7%) | 5 (3.1%) | 2 (1.2%) | 3 (9.7%) | 4 (12.9%) | 1 (3.2%) | 2 (6.4%) | 24 (7.7%) | 49 (15.6%) | 32 (10.2%) | 24 (7.7%) | 2 (4.0%) | 9 (18.0%) | 6 (12.0%) | 3 (6.0%) |
| Otitis | 2 (1.2%) | 2 (1.2%) | | 1 (0.6%) | | | | 1 (3.2%) | 6 (1.9%) | 5 (1.6%) | 3 (1.0%) | 1 (0.3%) | 2 (4.0%) | 1 (2.0%) | | |
| Swollen Glands | | | | | 1 (3.2%) | 1 (3.2%) | 1 (3.2%) | 1 (3.2%) | 4 (1.3%) | 17 (5.4%) | 2 (0.6%) | 3 (1.0%) | | 6 (12.0%) | | 1 (2.0%) |
| Conjunctivitis | | 1 (0.6%) | | | | | | | 6 (1.9%) | 4 (1.3%) | 2 (0.6%) | 5 (1.6%) | | | | |
| Gastrointestinal | 9 (5.7%) | 9 (5.7%) | 2 (1.2%) | 3 (1.9%) | 3 (9.7%) | 5 (16.1%) | 5 (16.1%) | 8 (25.8%) | 27 (8.6%) | 48 (15.3%) | 29 (9.3%) | 47 (15.0%) | 2 (4.0%) | 12 (24.0%) | 11 (22.0%) | 9 (18.0%) |
| Local Reaction | | | | | | | | | | | | 1 (0.3%) | | | | |
| Headache | 13 (8.2%) | 19 (11.9%) | 13 (8.2%) | 6 (3.8%) | 3 (9.7%) | 2 (6.4%) | | 1 (3.2%) | 5 (1.6%) | 9 (2.9%) | 2 (0.6%) | 2 (0.6%) | | 2 (4.0%) | 1 (2.0%) | |
| Irritability | 2 (1.2%) | 1 (0.6%) | 2 (1.2%) | 1 (0.6%) | 4 (12.9%) | 1 (3.2%) | | | 22 (7.0%) | 34 (10.9%) | 12 (3.8%) | 10 (3.2%) | | 5 (10.0%) | 3 (6.0%) | 2 (4.0%) |
| Malaise | 10 (6.3%) | 21 (13.2%) | 15 (9.4%) | 6 (3.8%) | 2 (6.4%) | 2 (6.4%) | 2 (6.4%) | 1 (3.2%) | 23 (7.3%) | 34 (10.9%) | 13 (4.2%) | 11 (3.5%) | 2 (4.0%) | 7 (14.0%) | 3 (6.0%) | 2 (4.0%) |
| Fever | 2 (1.2%) | 1 (0.6%) | 1 (0.6%) | 1 (0.6%) | 2 (6.4%) | 6 (19.4%) | 4 (12.9%) | 8 (25.8%) | 21 (6.7%) | 79 (25.2%) | 41 (13.1%) | 27 (8.6%) | 4 (8.0%) | 22 (44.0%) | 10 (20.0%) | 2 (4.0%) |
| Anorexia | 6 (3.8%) | 10 (6.3%) | 10 (6.3%) | 8 (5.0%) | 3 (9.7%) | 2 (6.4%) | 5 (16.1%) | 5 (16.1%) | 21 (6.7%) | 33 (10.5%) | 24 (7.7%) | 29 (9.3%) | 1 (2.0%) | 11 (22.0%) | 7 (14.0%) | 5 (10.0%) |
| Exanthema | | | | | | | | 1 (3.2%) | | 1 (0.3%) | 4 (1.3%) | 4 (1.3%) | | | | |
| Rubella-like Rash | | | | | | | | | | 2 (0.6%) | | | | | | |
| No Complaints | 137 (86.2%) | 124 (78.0%) | 136 (85.5%) | 146 (91.8%) | 21 (67.7%) | 18 (58.1%) | 21 (67.7%) | 15 (48.4%) | 234 (74.8%) | 152 (48.6%) | 210 (67.1%) | 204 (65.2%) | 41 (82.0%) | 16 (32.0%) | 27 (54.0%) | 33 (66.0%) |
| Physician's Surveillance Negative | 10 | 10 | 10 | 10 | | | | | | | | | | | | |
| Total Subjects | 169 | 169 | 169 | 169 | 31 | 31 | 31 | 31 | 313 | 313 | 313 | 313 | 50 | 50 | 50 | 50 |

Table 4: Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 96400 and for Their Unvaccinated Contact Controls (Study 220B)

| Clinical Complaint | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|--|--------------------------|---------------|---------------|---------------|-----------------------|----------------|----------------|----------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 10 (22.7%) | 6 (14.0%) | 4 (9.3%) | 4 (9.3%) | 83 (30.4%) | 92 (34.3%) | 42 (15.7%) | 51 (19.0%) | 24 (36.4%) | 29 (43.9%) | 12 (18.2%) | 13 (19.7%) |
| Swollen Glands | | | | | | | | 2 (0.7%) | | | | |
| Conjunctivitis | 3 (6.8%) | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | 8 (2.9%) | 6 (2.2%) | 1 (0.4%) | 1 (0.4%) | 1 (1.5%) | | | 1 (1.5%) |
| Gastrointestinal | 4 (9.1%) | 6 (14.0%) | 1 (2.3%) | 5 (11.6%) | 62 (22.7%) | 49 (18.3%) | 27 (10.1%) | 48 (17.9%) | 18 (27.3%) | 16 (24.2%) | 9 (13.6%) | 16 (24.2%) |
| Arthralgia | 1 (2.3%) | 1 (2.3%) | | | | | | | | | | |
| Headache | 1 (2.3%) | 1 (2.3%) | | 1 (2.3%) | 9 (3.3%) | 9 (3.4%) | 1 (0.4%) | 5 (1.9%) | 3 (4.5%) | 2 (3.0%) | | |
| Irritability | 3 (6.8%) | 4 (9.3%) | | | 21 (7.7%) | 29 (10.8%) | 7 (2.6%) | 6 (2.2%) | 7 (10.6%) | 6 (9.1%) | | 1 (1.5%) |
| Malaise | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | 18 (6.6%) | 17 (6.3%) | 2 (0.7%) | 3 (1.1%) | 4 (6.1%) | 5 (7.6%) | | 1 (1.5%) |
| Rubella | | | | | | | | 1 (0.4%) | | | | |
| Irrelevant | | | | | | 1 (0.4%) | | | | 1 (1.5%) | | |
| Fever | 5 (11.4%) | 6 (14.0%) | 4 (9.3%) | 1 (2.3%) | 61 (22.3%) | 58 (21.6%) | 24 (9.0%) | 19 (7.1%) | 14 (21.2%) | 19 (28.8%) | 9 (13.6%) | 7 (10.6%) |
| Anorexia | 1 (2.3%) | 1 (2.3%) | 1 (2.3%) | | 4 (1.5%) | 13 (4.8%) | 6 (2.2%) | 4 (1.5%) | 1 (1.5%) | 6 (9.1%) | 1 (1.5%) | |
| Musculoskeletal | | | | | | | 1 (0.4%) | 1 (0.4%) | | | | |
| Allergy | | | | | | 1 (0.4%) | 1 (0.4%) | 1 (0.4%) | | | | |
| Exanthema | | | | | | | | 1 (0.4%) | | | | |
| Rubella-like Rash | 2 (4.5%) | 2 (4.6%) | | | 3 (1.1%) | 5 (1.9%) | 3 (1.1%) | 10 (3.7%) | 2 (3.0%) | 3 (4.5%) | 1 (1.5%) | 2 (3.0%) |
| Measles-like Rash | | | | | | 1 (0.4%) | 1 (0.4%) | | | 1 (1.5%) | 1 (1.5%) | |
| Aggravated Infection at Injection Site | | | | | | | | 2 (0.7%) | | | | 1 (1.5%) |
| No Complaints | 25 (56.8%) | 28 (65.1%) | 32 (74.4%) | 34 (79.1%) | 127 (46.5%) | 121 (45.1%) | 184 (68.7%) | 168 (62.7%) | 27 (40.9%) | 18 (27.3%) | 43 (65.2%) | 32 (48.5%) |
| Physician's Surveillance Negative | | 1 | 1 | 1 | 14 | 19 | 19 | 19 | | | | |
| Total Subjects | 44 | 44 | 44 | 44 | 287 | 287 | 287 | 287 | 66 | 66 | 66 | 66 |

Table 4: Clinical Complaints Recorded for Children Vaccinated with Measles-Mumps-Rubella Vaccine Lot 92126 and for Their Unvaccinated Controls (Study 220C)

| Clinical Complaint | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|-----------------------------------|--------------------------|---------------|---------------|---------------|-----------------------|----------------|----------------|----------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 2 (7.1%) | 4 (14.3%) | 2 (7.1%) | 4 (14.3%) | 18 (7.9%) | 44 (19.3%) | 46 (20.2%) | 32 (14.0%) | 8 (7.8%) | 21 (20.4%) | 25 (24.3%) | 15 (14.6%) |
| Otitis | 1 (3.6%) | 1 (3.6%) | 1 (3.6%) | | 2 (0.9%) | 6 (2.6%) | 3 (1.3%) | 2 (0.9%) | 1 (1.0%) | 2 (1.9%) | 1 (1.0%) | 1 (1.0%) |
| Lymphadenopathy | | | | 1 (3.6%) | 1 (0.4%) | 2 (0.9%) | 4 (1.8%) | 5 (2.2%) | | | 3 (2.9%) | 5 (4.9%) |
| Conjunctivitis | | | | | 3 (1.3%) | 8 (3.5%) | 7 (3.1%) | 1 (0.4%) | | 2 (1.9%) | 1 (1.0%) | 1 (1.0%) |
| Gastrointestinal | | 1 (3.6%) | 3 (10.7%) | 2 (7.1%) | 14 (6.1%) | 28 (12.3%) | 16 (7.0%) | 13 (5.7%) | 5 (4.9%) | 12 (11.6%) | 5 (4.9%) | 3 (2.9%) |
| Rash | | | | | | 1 (0.4%) | 1 (0.4%) | 1 (0.4%) | | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) |
| Headache | | 1 (3.6%) | 1 (3.6%) | | | 3 (1.3%) | 2 (0.9%) | | | 1 (1.0%) | | |
| Irritability | | 2 (7.1%) | 1 (3.6%) | 1 (3.6%) | 11 (4.8%) | 33 (14.5%) | 18 (7.9%) | 11 (4.8%) | 6 (5.8%) | 15 (14.6%) | 8 (7.8%) | 4 (3.9%) |
| Malaise | | 2 (7.1%) | 1 (3.6%) | 1 (3.6%) | 13 (5.7%) | 32 (14.0%) | 20 (8.8%) | 10 (4.4%) | 6 (5.8%) | 13 (12.6%) | 7 (6.8%) | 5 (4.9%) |
| Measles | 1 (3.6%) | | | | 1 (0.4%) | 5 (2.2%) | | | | | | |
| Fever | 2 (7.1%) | 2 (7.1%) | 2 (7.1%) | 3 (10.7%) | 3 (1.3%) | 22 (9.6%) | 15 (6.6%) | 14 (6.1%) | 2 (1.9%) | 11 (10.7%) | 7 (6.8%) | 7 (6.8%) |
| Anorexia | | 2 (7.1%) | 1 (3.6%) | 1 (3.6%) | 7 (3.1%) | 27 (11.8%) | 18 (7.9%) | 8 (3.5%) | 1 (1.0%) | 10 (9.7%) | 6 (5.8%) | 4 (3.9%) |
| Allergy | | 2 (7.1%) | 2 (7.1%) | | 1 (0.4%) | 3 (1.3%) | 1 (0.4%) | 2 (0.9%) | 1 (1.0%) | 2 (1.9%) | | 1 (1.0%) |
| Exanthema | | | | | 1 (0.4%) | 4 (1.8%) | 4 (1.8%) | | 1 (1.0%) | 2 (1.9%) | 2 (1.9%) | |
| Measles-like Rash | 1 (3.6%) | 1 (3.6%) | 1 (3.6%) | | 1 (0.4%) | 6 (2.6%) | 5 (2.2%) | 1 (0.4%) | | | | |
| Whooping Cough | | | 1 (3.6%) | | | 1 (0.4%) | | 1 (0.4%) | | 1 (1.0%) | | 1 (1.0%) |
| No Complaint | 25 (89.3%) | 19 (67.9%) | 20 (71.4%) | 20 (71.4%) | 187 (82.0%) | 132 (57.9%) | 147 (64.5%) | 174 (76.3%) | 86 (83.5%) | 55 (53.4%) | 59 (57.3%) | 73 (70.9%) |
| Physician's Surveillance Negative | | | | | 7 | 7 | 7 | 7 | 2 | 2 | 2 | 2 |
| Total Subjects | 28 | 28 | 28 | 28 | 235 | 235 | 235 | 235 | 105 | 105 | 105 | 105 |

Table 4: Clinical Complaints Recorded for Children Vaccinated with Measles-Mumps-Rubella Vaccine Lot 92127 and for Their Unvaccinated Controls (Study 220C)

| Clinical Complaint | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|---------------------------|--------------------------|--------------|--------------|--------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | | 6 (54.5%) | 5 (45.5%) | 2 (18.2%) | 8 (6.2%) | 57 (44.5%) | 48 (37.5%) | 28 (21.9%) | 4 (6.3%) | 33 (52.4%) | 29 (46.0%) | 16 (25.1%) |
| Otitis | | 1 (9.1%) | | | | 4 (3.1%) | 2 (1.6%) | 3 (2.3%) | | 2 (3.2%) | 1 (1.6%) | 2 (3.2%) |
| Lymphadenopathy | | | 1 (9.1%) | | | 10 (7.8%) | 11 (8.6%) | 7 (5.5%) | | 5 (7.9%) | 5 (7.9%) | 5 (7.9%) |
| Conjunctivitis | | 1 (9.1%) | 1 (9.1%) | | 3 (2.3%) | 21 (16.4%) | 10 (7.8%) | 6 (4.7%) | 3 (4.8%) | 10 (15.9%) | 6 (9.5%) | 4 (6.3%) |
| Gastrointestinal | 1 (9.1%) | 1 (9.1%) | 1 (9.1%) | 2 (18.2%) | 5 (3.9%) | 13 (10.2%) | 9 (7.0%) | 8 (6.2%) | 2 (3.2%) | 6 (9.5%) | 6 (9.5%) | 3 (4.8%) |
| Headache | | | | | 2 (1.6%) | 4 (3.1%) | | 1 (0.8%) | 1 (1.6%) | 2 (3.2%) | | 1 (1.6%) |
| Irritability | 2 (18.2%) | 3 (27.3%) | 1 (9.1%) | 2 (18.2%) | 9 (7.0%) | 39 (30.5%) | 23 (18.0%) | 8 (6.2%) | 4 (6.3%) | 26 (41.3%) | 17 (27.0%) | 4 (6.3%) |
| Malaise | 3 (27.3%) | 3 (27.3%) | 1 (9.1%) | 1 (9.1%) | 12 (9.4%) | 27 (21.1%) | 6 (4.7%) | 5 (3.9%) | 7 (11.1%) | 16 (25.4%) | 6 (9.5%) | 5 (7.9%) |
| Fever | 1 (9.1%) | 1 (9.1%) | 3 (27.3%) | 3 (27.3%) | 4 (3.1%) | 21 (16.4%) | 16 (12.5%) | 18 (14.1%) | 3 (4.8%) | 16 (25.4%) | 8 (12.7%) | 8 (12.7%) |
| Anorexia | 1 (9.1%) | 1 (9.1%) | 1 (9.1%) | | 5 (3.9%) | 14 (10.9%) | 7 (5.5%) | 5 (3.9%) | 4 (6.3%) | 10 (15.9%) | 6 (9.5%) | 5 (7.9%) |
| Allergy | | | | | 2 (1.6%) | 7 (5.5%) | 7 (5.5%) | 2 (1.6%) | 2 (3.2%) | 6 (9.5%) | 5 (7.9%) | 1 (1.6%) |
| Exanthema | | | | | | 1 (0.8%) | 2 (1.6%) | 3 (2.3%) | | 1 (1.6%) | | 1 (1.6%) |
| No Complaint | 7 (63.6%) | 4 (36.4%) | 4 (36.4%) | 6 (54.5%) | 103 (80.5%) | 39 (30.5%) | 54 (42.2%) | 65 (50.8%) | 49 (77.8%) | 12 (19.0%) | 19 (30.2%) | 28 (44.4%) |
| Total Subjects | 11 | 11 | 11 | 11 | 128 | 128 | 128 | 128 | 63 | 63 | 63 | 63 |

Table 4: Clinical Complaints Recorded for Children Vaccinated with Measles-Mumps-Rubella Vaccine Lot 96400 and for Their Unvaccinated Controls (Study 220C)

| Clinical Complaint | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|-----------------------------------|--------------------------|---------------|---------------|---------------|-----------------------|----------------|----------------|----------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 1 (4.0%) | 3 (12.0%) | 1 (4.0%) | 3 (12.0%) | 15 (6.7%) | 19 (8.5%) | 14 (6.2%) | 19 (8.5%) | 4 (4.4%) | 5 (5.5%) | 3 (3.3%) | 8 (8.8%) |
| Otitis | 1 (4.0%) | | | | 1 (0.4%) | | 1 (0.4%) | 1 (0.4%) | | | | |
| Otitis Media | | | | | 1 (0.4%) | | | | | | | |
| Lymphadenopathy | | | | 1 (4.0%) | 1 (0.4%) | 4 (1.8%) | 3 (1.3%) | 2 (0.9%) | | | | |
| Conjunctivitis | 1 (4.0%) | 1 (4.0%) | | | 4 (1.3%) | 6 (2.7%) | | 1 (0.4%) | 1 (1.1%) | 2 (2.2%) | | 1 (1.1%) |
| Gastrointestinal | 1 (4.0%) | 1 (4.0%) | 1 (4.0%) | 2 (8.0%) | 20 (8.9%) | 38 (17.0%) | 17 (7.6%) | 10 (4.5%) | 13 (14.3%) | 20 (22.0%) | 9 (9.9%) | 7 (7.7%) |
| Headache | | | | | 5 (2.2%) | 9 (4.0%) | 6 (2.7%) | 2 (0.9%) | 2 (2.2%) | 4 (4.4%) | 2 (2.2%) | 1 (1.1%) |
| Irritability | 1 (4.0%) | 1 (4.0%) | | 1 (4.0%) | 6 (2.7%) | 14 (6.2%) | 2 (0.9%) | 3 (1.3%) | 3 (3.3%) | 6 (6.6%) | 1 (1.1%) | 1 (1.1%) |
| Malaise | | 1 (4.0%) | 1 (4.0%) | 1 (4.0%) | 6 (2.7%) | 11 (4.9%) | 4 (1.8%) | 6 (2.7%) | 4 (4.4%) | 7 (7.7%) | 2 (2.2%) | 5 (5.5%) |
| Measles | | 1 (4.0%) | | | | 1 (0.4%) | | | | | | |
| Fever | 1 (4.0%) | 3 (12.0%) | 2 (8.0%) | 5 (20.0%) | 12 (5.4%) | 49 (21.9%) | 19 (8.5%) | 32 (14.3%) | 8 (8.8%) | 23 (25.3%) | 6 (6.6%) | 13 (14.3%) |
| Anorexia | | 1 (4.0%) | | | 11 (4.9%) | 19 (8.5%) | 7 (3.1%) | 4 (1.8%) | 6 (6.6%) | 12 (13.2%) | 6 (6.6%) | 2 (2.2%) |
| Allergy | | | | | 1 (0.4%) | 1 (0.4%) | | 1 (0.4%) | | | | 1 (1.1%) |
| Exanthema | | | | | 1 (0.4%) | 1 (0.4%) | 1 (0.4%) | 2 (0.9%) | | | | 1 (1.1%) |
| Measles-like Rash | | 1 (4.0%) | 1 (4.0%) | | | 1 (0.4%) | 1 (0.4%) | | | | | |
| No Complaint | 22 (88.0%) | 19 (76.0%) | 21 (84.0%) | 14 (56.0%) | 166 (74.1%) | 120 (53.6%) | 172 (76.8%) | 164 (73.2%) | 61 (67.0%) | 43 (47.3%) | 71 (78.0%) | 64 (70.3%) |
| Physician's Surveillance Negative | | | | | 2 | 2 | 2 | 2 | | | | |
| Total Subjects | 25 | 25 | 25 | 25 | 226 | 226 | 226 | 226 | 91 | 91 | 91 | 91 |

Trivalent Measles-Mumps-Rubella Vaccine
Stokes, et al.

TABLE 6.—Miscellaneous Clinical Complaints Among Triple Seronegative Children Given Trivalent Vaccine Compared with Unvaccinated Controls (Suburban Philadelphia).

| Complaint | Vaccinated Children (228) | | | | Contact Controls (106) | | | |
|----------------------------|---------------------------|------------|------------|------------|------------------------|-----------|-----------|-----------|
| | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Conjunctivitis | | 1 (0.4) | | | | | | |
| Otitis | 3 (1.3%) | 5 (2.2) | 3 (1.3) | 7 (3.1) | | | 1 (0.9) | 1 (0.9) |
| Upper respiratory illness | 41 (18.0) | 56 (24.6) | 28 (12.3) | 33 (14.5) | 9 (8.5) | 17 (16.0) | 11 (10.4) | 11 (10.4) |
| Lymphadenopathy | | 3 (1.3) | | | | | 1 (0.9) | |
| Gastroenteritis | 15 (6.6) | 18 (7.9) | 11 (4.8) | 7 (3.1) | 3 (2.8) | 2 (1.9) | 1 (0.9) | |
| Rash (non-measles) | 10 (4.4) | 6 (2.6) | 4 (1.8) | 4 (1.8) | 2 (1.9) | 2 (1.9) | 1 (0.9) | 1 (0.9) |
| Local reaction - inj. site | 1 (0.4) | | | | | | | |
| Headache | | | | 1 (0.4) | 1 (0.9) | | | 1 (0.9) |
| Irritability | 15 (6.6) | 17 (7.5) | 6 (2.6) | 5 (2.2) | 2 (1.9) | | | |
| Malaise | 1 (0.4) | 1 (0.4) | | | | | | |
| Anorexia | 4 (1.8) | 5 (2.2) | 1 (0.4) | 2 (0.9) | 1 (0.9) | | | |
| Measles-like rash | | 9 (3.9) | 2 (0.9) | | | | | |
| Fatigue | 1 (0.4) | | | | | 1 (0.9) | | |
| Unrelated illness | 10 (4.4) | 12 (5.3) | 11 (4.8) | 15 (6.6) | | 1 (0.9) | 1 (0.9) | 1 (0.9) |
| No complaints | 152 (66.7) | 136 (59.6) | 177 (77.6) | 164 (71.9) | 88 (83.0) | 85 (80.2) | 91 (85.8) | 92 (86.8) |

Trivalent Measles-Mumps-Rubella Vaccine
Stokes, et al.

TABLE 7.--Miscellaneous Clinical Complaints Among Triple Seronegative Children Given Trivalent Vaccine Compared with Unvaccinated Controls (Costa Rica-San Salvador).

| Complaint | Vaccinated Children (457) | | | | Contact Controls (175) | | | |
|---------------------------|---------------------------|------------|------------|------------|------------------------|------------|------------|------------|
| | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Conjunctivitis | 5 (1.1%) | 15 (3.3) | 8 (1.8) | 8 (1.8) | 5 (2.9) | 4 (2.3) | 3 (1.7) | 2 (1.1) |
| Otitis | 3 (0.7) | 8 (1.8) | 2 (0.4) | 3 (0.7) | 2 (1.1) | 3 (1.7) | 1 (0.6) | 1 (0.6) |
| Upper respiratory illness | 52 (11.4) | 113 (24.7) | 84 (18.4) | 63 (13.8) | 18 (10.3) | 32 (18.3) | 19 (10.9) | 19 (10.9) |
| Lymphadenopathy | | 12 (2.6) | 8 (1.8) | 11 (2.4) | 1 (0.6) | 3 (1.7) | 2 (1.1) | 3 (1.7) |
| Gastroenteritis | 47 (10.3) | 88 (19.3) | 49 (10.7) | 46 (10.1) | 11 (6.3) | 24 (13.7) | 18 (10.3) | 24 (13.7) |
| Natural measles | | | | | 1 (0.6) | 1 (0.6) | | |
| Fever | 24 (5.3) | 102 (22.3) | 45 (9.8) | 37 (8.1) | 12 (6.9) | 23 (13.1) | 18 (10.3) | 22 (12.6) |
| Headache | 7 (1.5) | 15 (3.3) | 3 (0.7) | 3 (0.7) | 5 (2.9) | 6 (3.4) | 1 (0.6) | 2 (1.1) |
| Irritability | 28 (6.1) | 85 (18.6) | 42 (9.2) | 20 (4.4) | 12 (6.9) | 19 (10.9) | 7 (4.0) | 10 (5.7) |
| Malaise | 39 (8.5) | 68 (14.9) | 26 (5.7) | 21 (4.6) | 9 (5.1) | 15 (8.6) | 11 (6.3) | 9 (5.1) |
| Anorexia | 23 (5.0) | 67 (14.7) | 35 (7.7) | 22 (4.8) | 9 (5.1) | 16 (9.1) | 12 (6.9) | 8 (4.6) |
| Measles-like rash | | 1 (0.2) | 1 (0.2) | | 1 (0.6) | 2 (1.1) | 2 (1.1) | |
| Exanthema | 1 (0.2) | 4 (0.9) | 3 (0.7) | 4 (0.9) | | 1 (0.6) | 1 (0.6) | 1 (0.6) |
| Rubella-like rash | 2 (0.4) | 3 (0.7) | 1 (0.2) | 2 (0.4) | 2 (1.1) | 2 (1.1) | | |
| Arthralgia | | | | | 1 (0.6) | 1 (0.6) | | |
| Unrelated illness | 3 (0.7) | 11 (2.4) | 6 (1.3) | 6 (1.3) | | 2 (1.1) | 3 (1.7) | |
| No complaints | 318 (69.6) | 183 (40.0) | 276 (60.4) | 294 (64.3) | 127 (72.6) | 106 (60.6) | 121 (69.1) | 115 (65.7) |

Table 3

Clinical Complaints Recorded for Children Vaccinated with
Combined Measles-Mumps-Rubella Vaccine Lot 12238 (Study #253)

| Clinical Complaint | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|---------------------------|-----------------------|---------------|----------------|----------------|---|---------------|---------------|---------------|
| | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | | 4 (3.4%) | 2 (1.7%) | 3 (2.6%) | | 3 (5.1%) | 1 (1.7%) | 3 (5.1%) |
| Otitis | 1 (0.9%) | 5 (4.3%) | | | 1 (1.7%) | 1 (1.7%) | | |
| Swollen Glands | | 1 (0.9%) | | | | | | |
| Conjunctivitis | 1 (0.9%) | 1 (0.9%) | | | | | | |
| Gastrointestinal | 2 (1.7%) | 7 (6.0%) | 3 (2.6%) | 2 (1.7%) | 1 (1.7%) | 5 (8.5%) | 3 (5.1%) | 2 (3.4%) |
| Headache | | 1 (0.9%) | | | | 1 (1.7%) | | |
| Irritability | 4 (3.4%) | 23 (19.7%) | 4 (3.4%) | 10 (8.5%) | 4 (6.8%) | 16 (27.1%) | 3 (5.1%) | 6 (10.2%) |
| Malaise | 4 (3.4%) | 23 (19.7%) | 4 (3.4%) | 10 (8.5%) | 4 (6.8%) | 16 (27.1%) | 3 (5.1%) | 6 (10.2%) |
| Irrelevant | | 1 (0.9%) | | | | 1 (1.7%) | | |
| Fever | 3 (2.6%) | 20 (17.1%) | 3 (2.6%) | 6 (5.1%) | 3 (5.1%) | 13 (22.0%) | 2 (3.4%) | 4 (6.8%) |
| Anorexia | 6 (5.1%) | 22 (18.8%) | 4 (3.4%) | 8 (6.8%) | 5 (8.5%) | 16 (27.1%) | 3 (5.1%) | 5 (8.5%) |
| Allergy | | 2 (1.7%) | 2 (1.7%) | | | 2 (3.4%) | 2 (3.4%) | |
| No Complaints | 108 (92.3%) | 83 (70.9%) | 110 (94.0%) | 106 (90.6%) | 53 (89.8%) | 39 (66.1%) | 53 (89.8%) | 52 (88.1%) |
| Total Subjects | 117 | 117 | 117 | 117 | 59 | 59 | 59 | 59 |

Table 4

Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 92127 and for Their Unvaccinated Contact Controls (Study 246)

| Clinical Complaints | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|---------------------------|--------------------------|--------------|-------------|-------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 2 (33.3%) | 2 (33.3%) | | | 36 (32.7%) | 48 (43.6%) | 18 (16.4%) | 13 (11.8%) | 21 (32.8%) | 29 (45.3%) | 9 (14.1%) | 8 (12.5%) |
| Conjunctivitis | | | | | 2 (1.8%) | 3 (2.7%) | 2 (1.8%) | | 1 (1.6%) | 2 (3.1%) | 1 (1.6%) | |
| Gastrointestinal | | | | | 4 (3.6%) | 6 (5.5%) | | | 4 (6.2%) | 4 (6.2%) | | |
| Headache | | | | | 5 (4.5%) | 2 (1.8%) | | | 1 (1.6%) | 1 (1.6%) | | |
| Irritability | | | | | 11 (10.0%) | 9 (8.2%) | 1 (0.9%) | 1 (0.9%) | 7 (10.9%) | 6 (9.4%) | | |
| Malaise | | | | | 10 (9.1%) | 3 (2.7%) | 2 (1.8%) | 1 (0.9%) | 4 (6.2%) | 2 (3.1%) | 1 (1.6%) | |
| Measles | | | | | | 1 (0.9%) | | | | | | |
| Anorexia | | | | | 10 (9.1%) | 12 (10.9%) | 5 (4.5%) | 3 (2.7%) | 6 (9.4%) | 6 (9.4%) | 3 (4.7%) | 2 (3.1%) |
| Exanthema | | | | | 1 (0.9%) | 2 (1.8%) | 1 (0.9%) | | 1 (1.6%) | 1 (1.6%) | | |
| No Complaints | 4 (66.7%) | 4 (66.7%) | 6 (100%) | 6 (100%) | 62 (56.4%) | 55 (50.0%) | 87 (79.1%) | 94 (85.5%) | 36 (56.2%) | 32 (50.0%) | 51 (79.7%) | 53 (82.8%) |
| Total Subjects | 6 | 6 | 6 | 6 | 110 | 110 | 110 | 110 | 64 | 64 | 64 | 64 |

Table

Clinical Complaints Recorded for Children Vaccinated with Combined Measles-Mumps-Rubella Vaccine Lot 96400 and for Their Unvaccinated Contact Controls (Study 246)

| Clinical Complaints | Contact Control Children | | | | Total Vaccinees | | | | Initially Seronegative to Measles-Mumps-Rubella | | | |
|---------------------------|--------------------------|--------------|--------------|-------------|-----------------------|---------------|---------------|---------------|---|---------------|---------------|---------------|
| | Days Observed | | | | Days Post-Vaccination | | | | Days Post-Vaccination | | | |
| | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 | 1-4 | 5-12 | 13-18 | 19-28 |
| Upper Respiratory Illness | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | | 31 (39.7%) | 32 (41.0%) | 7 (9.0%) | 5 (6.4%) | 12 (32.4%) | 16 (43.2%) | 6 (16.2%) | 2 (5.4%) |
| Otitis | | | | | | 1 (1.3%) | | | | | | |
| Swollen Glands | | | | | 1 (1.3%) | 1 (1.3%) | | | | | | |
| Conjunctivitis | 1 (33.3%) | 1 (33.3%) | | | | | | | | | | |
| Gastrointestinal | | | | | | 2 (2.6%) | 1 (1.3%) | 3 (3.8%) | | 2 (5.4%) | 1 (2.7%) | 2 (5.4%) |
| Headache | | | | | 3 (3.8%) | 1 (1.3%) | | | | | | |
| Irritability | 1 (33.3%) | 1 (33.3%) | | | 5 (6.4%) | 3 (3.8%) | | | 1 (2.7%) | 1 (2.7%) | | |
| Malaise | 2 (66.7%) | 2 (66.7%) | | | 8 (10.3%) | 3 (3.8%) | | | 2 (5.4%) | 1 (2.7%) | | |
| Anorexia | | | | | 1 (1.3%) | 5 (6.4%) | 1 (1.3%) | 1 (1.3%) | | 2 (5.4%) | 1 (2.7%) | 1 (2.7%) |
| Exanthema | | | | | 1 (1.3%) | 1 (1.3%) | | | 1 (2.7%) | 1 (2.7%) | | |
| No Complaints | 1 (33.3%) | 1 (33.3%) | 2 (66.7%) | 3 (100%) | 46 (59.0%) | 44 (56.4%) | 70 (89.7%) | 71 (91.0%) | 25 (67.6%) | 20 (54.1%) | 30 (81.1%) | 33 (89.2%) |
| Total Subjects | 3 | 3 | 3 | 3 | 78 | 78 | 78 | 78 | 37 | 37 | 37 | 37 |